Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
64.93
+2.13 (3.39%)
At close: Oct 31, 2025, 4:00 PM EDT
64.01
-0.92 (-1.42%)
After-hours: Oct 31, 2025, 7:53 PM EDT
Nektar Therapeutics Revenue
Nektar Therapeutics had revenue of $11.18M in the quarter ending June 30, 2025, a decrease of -52.42%. This brings the company's revenue in the last twelve months to $74.93M, down -19.56% year-over-year. In the year 2024, Nektar Therapeutics had annual revenue of $98.43M with 9.22% growth.
Revenue (ttm)
$74.93M
Revenue Growth
-19.56%
P/S Ratio
12.15
Revenue / Employee
$1,228,426
Employees
61
Market Cap
1.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 98.43M | 8.31M | 9.22% |
| Dec 31, 2023 | 90.12M | -1.93M | -2.10% |
| Dec 31, 2022 | 92.06M | -9.85M | -9.67% |
| Dec 31, 2021 | 101.91M | -51.01M | -33.36% |
| Dec 31, 2020 | 152.92M | 38.30M | 33.41% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
NKTR News
- 2 days ago - Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London - PRNewsWire
- 4 days ago - Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets - PRNewsWire
- 5 days ago - San Francisco is making a comeback. So are these stocks from the City by the Bay - CNBC
- 11 days ago - Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting - PRNewsWire
- 6 weeks ago - Why Is Nektar Therapeutics Stock Trading Lower On Thursday? - Benzinga
- 6 weeks ago - Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025 - PRNewsWire
- 7 weeks ago - Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025 - PRNewsWire
- 2 months ago - What's Going On With Nektar Therapeutics Stock On Thursday? - Benzinga